Indy Hematology Review
Avatar

Treatment Strategies in MDS and ALL: Removing Bad Humor & Targeting Aberrant Signaling

By Indy Hematology Review FEATURING Richard Stone
By Indy Hematology Review FEATURING Richard Stone
32 views
April 22, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
16:55
Moffitt Cancer Center

Making Sense of the New Classification Systems for MDS in 2024

Feat. R. Komrokji
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
32:04
Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman
04:02
Michael Burke

Updated Results from the BLAST and TOWER Studies: Safety and Efficac…

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
07:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
28:07
Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock
16:50
MDS Foundation

Pre-MDS States: How to Manage CHIP, CCUS and ICUS in the Clinic

Feat. M. Savona
33:37
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: MDS

Feat. G. Garcia-Manero